Protein replacement therapies for rare diseases: a breeze for regulatory approval?
- PMID: 23536010
- DOI: 10.1126/scitranslmed.3005007
Protein replacement therapies for rare diseases: a breeze for regulatory approval?
Abstract
Protein replacement therapies for rare monogenic diseases have a higher probability of regulatory approval compared with biologics, small molecules, and grant-funded orphan drugs.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
